早期非小细胞肺癌纵隔淋巴结EBUS-TBNA诊断效能的前瞻性研究
本研究前瞻性纳入PET/CT分期为N0/N1且无远处转移的肺癌患者75例,评估纵隔淋巴结EBUS-TBNA的诊断敏感性。结果显示20%患者实际为N2期,EBUS-TBNA对N2病变的敏感性为40%(95%CI:16.3-67.7%),虽优于单用PET/CT,但低于既往大块纵隔病变患者的数据。
要点
- PET/CT诊断N0/N1的肺癌患者中,20%实际存在N2纵隔淋巴结转移。
- EBUS-TBNA对此类N2病变的敏感性仅40%(95%CI:16.3-67.7%)。
- EBUS-TBNA可提高诊断准确性,但敏感性低于既往大块纵隔病变患者数据。
核心结论
- PET/CT诊断为N0/N1的肺癌患者中约20%实际为N2期,EBUS-TBNA可识别其中部分患者,但敏感性为40%(95%CI:16.3-67.7%),低于历史对照数据。
研究设计与样本
- 前瞻性研究,纳入75例病理证实或疑似肺癌、PET/CT分期为N0/N1且无远处转移(M0)并接受分期EBUS-TBNA的患者。
- 主要终点为EBUS-TBNA的敏感性,参考标准为手术分期或EBUS证实N2/N3时的EBUS分期。
主要发现
- 75例患者中平均肿瘤大小3.52 cm(±1.63)。
- EBUS-TBNA对N2病变的敏感性为40%(95%CI:16.3-67.7%)。
临床怎么用
- 对PET/CT分期为N0/N1的早期肺癌患者,行EBUS-TBNA分期可提高诊断准确性,但阴性结果不能排除N2病变。
- 此类患者若EBUS-TBNA阴性,仍需考虑手术分期以明确纵隔淋巴结状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Standard nodal staging of lung cancer consists of positron emission tomography/computed tomography (PET/CT), followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) if PET/CT shows mediastinal lymphadenopathy. Sensitivity of EBUS-TBNA in patients with N0/N1 disease by PET/CT is unclear and largely based on retrospective studies. We assessed the sensitivity of EBUS-TBNA in this setting. METHODS: We enrolled patients with proven or suspected lung cancer staged as N0/N1 by PET/CT and without metastatic disease (M0), who underwent staging EBUS-TBNA. Primary outcome was sensitivity of EBUS-TBNA compared with a composite reference standard of surgical stage or EBUS-TBNA stage if EBUS demonstrated N2/N3 disease. RESULTS: Seventy-five patients were included in the analysis. Mean tumour size was 3.52 cm (±1.63). Fifteen of 75 patients (20%) had N2 disease. EBUS-TBNA identified six while nine were only identified at surgery. Sensitivity of EBUS-TBNA for N2 disease was 40% (95% CI: 16.3-67.7%). CONCLUSION: A significant proportion of patients with N0/N1 disease by PET/CT had N2 disease (20%) and EBUS-TBNA identified a substantial fraction of these patients, thus improving diagnostic accuracy compared with PET/CT alone. Sensitivity of EBUS-TBNA however appears lower compared with historical data from patients with larger volume mediastinal disease. Therefore, strategies to improve EBUS-TBNA accuracy in this population should be further explored.
引用
- Vial MR, O'Connell OJ, Grosu HB, et al. Diagnostic performance of endobronchial ultrasound-guided mediastinal lymph node sampling in early stage non-small cell lung cancer: A prospective study. Respirology. 2017. PMID: 28857362. doi:10.1111/resp.13162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。